Vista Pharmaceuticals has inked a non-disclosure agreement (NDA), to acquire a complex abbreviated new drug application (ANDA) for Urocare.

This ANDA will be manufactured at another USFDA approved Contract Manufacturing Facility (CMO), for 2 years. As per the latest IMS data, the company has already filed a complex ANDA in September 2017, which targets Cardialgy segment with a market size of $200 million.

Furthermore, the company is expecting good revenues and profits from this product as it is having limited competition in the market.

Read EquityPandit’s Technical Analysis of Nifty Pharma Outlook for the Week